SG11201806623VA - Bacteria over-expressing c-di-amp and therapeutic methods - Google Patents
Bacteria over-expressing c-di-amp and therapeutic methodsInfo
- Publication number
- SG11201806623VA SG11201806623VA SG11201806623VA SG11201806623VA SG11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- baltimore
- mycobacterium
- pct
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 241000186359 Mycobacterium Species 0.000 abstract 4
- 239000013604 expression vector Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000006303 Chaperonin 60 Human genes 0.000 abstract 1
- 108010058432 Chaperonin 60 Proteins 0.000 abstract 1
- 101710095468 Cyclase Proteins 0.000 abstract 1
- 108090000129 Diadenylate cyclases Proteins 0.000 abstract 1
- 241000896693 Disa Species 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 241000186366 Mycobacterium bovis Species 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940114179 mycobacterium bovis Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/130616 Al 18 August 2016 (18.08.2016) WIPO I PCT 11111111111111 0 11101 010 11111 0111 11111 01110111 01111101E11011 111111111111111 0111111 (51) International Patent Classification: A61K 39/04 (2006.01) A61K 48/00 (2006.01) A61K 35/74 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/017248 (22) International Filing Date: 10 February 2016 (10.02.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/114,610 11 February 2015 (11.02.2015) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, Maryland 21218 (US). (72) Inventors: BISHAI, William R.; 1202 Ridervale Road, Baltimore, Maryland 21204 (US). DEY, Ruchi Jain; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). DEY, Bappaditya; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). (74) Agent: FEULNER, Gregory; 100 N. Charles Street, 5th Floor, Baltimore, Maryland 21201 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 16/ 1306 16 Al (54) Title: BACTERIA OVER-EXPRESSING C-DI-AMP AND THERAPEUTIC METHODS (57) : The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobac- terium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a my - cobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.?
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114610P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017248 WO2016130616A1 (en) | 2015-02-11 | 2016-02-10 | Bacteria over-expressing c-di-amp and therapeutic methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806623VA true SG11201806623VA (en) | 2018-09-27 |
Family
ID=56615726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806623VA SG11201806623VA (en) | 2015-02-11 | 2016-02-10 | Bacteria over-expressing c-di-amp and therapeutic methods |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US10130663B2 (en) |
| CA (1) | CA3013713A1 (en) |
| SG (1) | SG11201806623VA (en) |
| WO (1) | WO2016130616A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806623VA (en) * | 2015-02-11 | 2018-09-27 | Univ Johns Hopkins | Bacteria over-expressing c-di-amp and therapeutic methods |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2018129404A1 (en) * | 2017-01-06 | 2018-07-12 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| EP3651782A1 (en) * | 2017-07-12 | 2020-05-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| JP2021512144A (en) * | 2018-01-26 | 2021-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｌｉｆｏｒｎｉａ | Intranasal delivery of tuberculosis vaccine containing cyclic dinucleotide adjuvant |
| US12359209B2 (en) * | 2018-04-17 | 2025-07-15 | The Johns Hopkins Unversity | Recombinant therapeutic interventions for cancer |
| CA3097569A1 (en) * | 2018-04-17 | 2019-10-24 | The Johns Hopkins University | Recombinant therapeutic interventions for cancer |
| CN116528890A (en) * | 2020-10-01 | 2023-08-01 | 约翰霍普金斯大学 | BCG-based vaccine compositions and methods of use thereof |
| CN112342233B (en) * | 2020-11-10 | 2022-08-26 | 上海陶宇晟生物技术有限责任公司 | Polynucleotide for increasing c-di-AMP production when bacteria express DacA |
| CN115337393A (en) * | 2022-07-07 | 2022-11-15 | 中国人民解放军空军军医大学 | Application of a recombinant BCG-DisA that overexpresses Mycobacterium tuberculosis c-di-AMP synthetase |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001294834A1 (en) * | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| US9061048B2 (en) * | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
| WO2013040548A2 (en) | 2011-09-17 | 2013-03-21 | Yale University | Fluoride-responsive riboswitchs, fluoride transporters, and methods of use |
| WO2013066264A1 (en) | 2011-10-31 | 2013-05-10 | Nanyang Technological University | Enzymatic synthesis of cyclic and linear diadenosine monophosphate |
| JP5650780B2 (en) | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | Vaccine composition |
| NZ702392A (en) | 2012-06-08 | 2017-03-31 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| CA2886456A1 (en) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US20140220079A1 (en) | 2013-02-05 | 2014-08-07 | Nitto Denko Corporation | Vaccine composition for mucosal administration |
| IN2014CH00396A (en) | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
| CN103961702B (en) | 2013-02-05 | 2019-04-09 | 日东电工株式会社 | WT1 peptide cancer vaccine composition for mucosal administration |
| CA2840941A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for transdermal administration |
| AU2014268836B2 (en) | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| SG11201806623VA (en) * | 2015-02-11 | 2018-09-27 | Univ Johns Hopkins | Bacteria over-expressing c-di-amp and therapeutic methods |
| SI3317301T1 (en) | 2015-07-29 | 2021-10-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN105367617A (en) | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | Derivative based on c-di-AMP, tat polypeptide and application of derivative in inhibitor in type I interferon micromolecules |
| WO2017075477A1 (en) | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN106554416B (en) | 2015-12-09 | 2019-03-15 | 聊城市奥润生物医药科技有限公司 | A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor |
| CN106539814A (en) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | Interferon gene stimulatory protein(SP)（STING）Application of the agonist in the diseases such as resisting rheumatoid arthritis |
| WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
| JP2019514939A (en) | 2016-04-26 | 2019-06-06 | クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． | Therapeutic induction of innate immune response in target tissues |
| CN106539816A (en) | 2016-04-30 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | Application of the ring dinucleotides in preventing and treating multiple sclerosis |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| WO2018026717A1 (en) | 2016-08-01 | 2018-02-08 | Aduro Biotech, Inc. | Protein expression enhancer sequences and use thereof |
| TWI874884B (en) | 2016-08-10 | 2025-03-01 | 日商領先基因生技股份有限公司 | Method for detecting presence or absence of target nucleic acid sequence at target site |
| CA3097569A1 (en) * | 2018-04-17 | 2019-10-24 | The Johns Hopkins University | Recombinant therapeutic interventions for cancer |
-
2016
- 2016-02-10 SG SG11201806623VA patent/SG11201806623VA/en unknown
- 2016-02-10 WO PCT/US2016/017248 patent/WO2016130616A1/en active Application Filing
- 2016-02-10 CA CA3013713A patent/CA3013713A1/en active Pending
- 2016-02-10 US US15/550,434 patent/US10130663B2/en active Active
-
2018
- 2018-10-01 US US16/147,916 patent/US10842828B2/en active Active
-
2020
- 2020-11-19 US US16/953,162 patent/US11590177B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3013713A1 (en) | 2016-08-18 |
| US10130663B2 (en) | 2018-11-20 |
| US20180028577A1 (en) | 2018-02-01 |
| US20190030091A1 (en) | 2019-01-31 |
| US11590177B2 (en) | 2023-02-28 |
| WO2016130616A1 (en) | 2016-08-18 |
| US10842828B2 (en) | 2020-11-24 |
| US20210145896A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201810196RA (en) | Cancer treatments | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |